Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
about
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionManagement of hepatitis c genotype 4 in the liver transplant settingKASL clinical practice guidelines: management of hepatitis CSystematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1Entry inhibitors: New advances in HCV treatmentEfficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-AnalysisNew approaches in the treatment of hepatitis CHepatitis C genotype 4: The past, present, and futureHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceRole of Marine Natural Products in the Genesis of Antiviral AgentsPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewChronic hepatitis C: future treatmentSofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potentialThyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspectiveAntiviral treatment of hepatitis C virus infection and factors affecting efficacyReview article: HCV genotype 3 – the new treatment challengeChutes and ladders in hepatitis C nucleoside drug developmentEmerging therapies for the treatment of hepatitis CAntiviral therapies for chronic hepatitis C virus infection with cirrhosisEfficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-AnalysisRecommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineThe epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analysesHepatitis C genotype 3 disease.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015Hepatitis C treatment: where are we now?CUFA algorithm: assessment of liver fibrosis using routine laboratory data.HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeVirologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysisEarly Experience of Sofosbuvir based Combination Therapy in "Real-Life" Cohort with Chronic Hepatitis-C Infection.The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.Global distribution and prevalence of hepatitis C virus genotypes.Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise reviewDirect-acting antivirals for chronic hepatitis C.Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders
P2860
Q26741123-3BC38D26-CF9F-490F-B814-7C0FF21971C4Q26746563-E9261BCD-33E7-42B4-9AF2-2B4E97CFF3C1Q26749326-59002FCD-8D29-4508-A051-E62919B400C1Q26752471-0B104FF9-68C0-423A-9EDB-9F6A9607A8E0Q26768128-F87D6CEB-0F55-4CFB-8306-3A75CAF7C15EQ26770817-700FADCE-1BCB-421D-A3CC-251CB65316ABQ26771458-3935E570-01A1-40F7-885A-24CCFC2008EBQ26773271-8CD571EF-0323-4A3D-987A-BEE72EBD1AC7Q26775815-034A77EF-B520-4817-B83B-2FD89731081FQ26782405-06EA7CBE-33B4-4245-AF84-5FC06C921D40Q26783056-ED91A2B9-0A33-4BB3-BE0B-91C3EA6F1161Q26796360-0D6BE1C3-1028-4A30-A574-08FD70715B43Q26798477-6B720C0D-D55D-47DD-A351-F1D930198E1AQ26800050-27742DC6-186E-442A-8AC0-97F3816F22BCQ26824075-373A0BA1-FDF8-4B8D-BCEE-28B3497D0208Q26827322-C431A0D1-963D-4A77-BCD9-C4C1114E2489Q26827517-8D2418A4-0153-4BF6-BC62-98F5B14BF332Q26851810-FE139F91-D1F1-4792-BE6B-F9F2AC37D729Q26864571-20325C48-2D2A-4AC4-9DCD-67C8B278606EQ26998630-6768AE61-6A2D-4EEF-BA48-5CF7CCDC7F7DQ27003319-6A642611-7ADF-41B0-A19A-980AA0962A97Q27022794-A3FA79C6-A8A7-4AE8-AA5C-C51A259154F5Q28074783-A8132AAB-FE82-4B0E-AB06-51386B55DE28Q28076883-B085C648-56B2-48EC-9F0C-4E45122937A7Q28087794-B53A1076-3107-45B7-95A8-5733F0365682Q30244065-6ACB95EB-8F27-4EF9-9AAB-4B4F09D3E3FFQ30355190-DF5473C4-2740-46D9-96F1-1B898A432554Q30375305-BBB1D5D4-0A25-404A-822F-4C6800C40483Q30378509-9134DEB8-8AFF-40D6-8163-2F5C354D3FCAQ30834803-38A5B7E1-1385-476B-8EAC-D16C04E958A0Q31012317-10B71DA4-2E15-46BB-A94F-3F14F3402245Q33419423-CDD6A898-BB45-43EF-A7C2-34CEE556925FQ33440436-F92BA07C-97A7-4F72-9F9E-837256A3E140Q33582596-E4ADA67E-4829-4A07-9EFC-6F9720AA98DEQ33666545-55E657EE-BE2F-4961-91BF-5E0EA337B24AQ34113840-106CF17E-53D2-453A-9CF7-7C317D88402EQ34431175-77BCAD09-E65E-4FBD-A1B9-9F6ED83FE1BFQ34439125-4529CFAD-E6B3-4323-965D-8CF97C14316AQ34557595-A9EC0A04-6717-4E01-A149-F312FE48A895Q34597666-A00CDAA5-F1CC-4FD3-BF44-9F0BC0C0F07C
P2860
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@ast
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@en
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@nl
type
label
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@ast
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@en
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@nl
prefLabel
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@ast
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@en
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@nl
P2093
P921
P1476
Sofosbuvir in combination with ...... , double-blind, phase 2 trial.
@en
P2093
Aasim M Sheikh
Andrew Muir
Bradley Freilich
David E Bernstein
David R Nelson
Donald Jensen
Douglas T Dieterich
Edwin Dejesus
Efsevia Albanis
Eric Lawitz
P304
P356
10.1016/S1473-3099(13)70033-1
P577
2013-03-15T00:00:00Z